Kukje Pharma Co Ltd (002720) - Total Assets
Based on the latest financial reports, Kukje Pharma Co Ltd (002720) holds total assets worth ₩180.12 Billion KRW (≈ $122.06 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Kukje Pharma Co Ltd - Total Assets Trend (2011–2024)
This chart illustrates how Kukje Pharma Co Ltd's total assets have evolved over time, based on quarterly financial data. Also see Kukje Pharma Co Ltd (002720) total market value for the company's overall valuation and market capitalisation.
Kukje Pharma Co Ltd - Asset Composition Analysis
Current Asset Composition (December 2024)
Kukje Pharma Co Ltd's total assets of ₩180.12 Billion consist of 34.4% current assets and 65.6% non-current assets. Review total liabilities of Kukje Pharma Co Ltd to assess the company's total debt and financial obligations.
| Asset Category | Amount (KRW) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 5.2% |
| Accounts Receivable | ₩22.76 Billion | 13.8% |
| Inventory | ₩22.37 Billion | 13.5% |
| Property, Plant & Equipment | ₩0.00 | 0.0% |
| Intangible Assets | ₩870.10 Million | 0.5% |
| Goodwill | ₩0.00 | 0.0% |
Asset Composition Trend (2011–2024)
This chart illustrates how Kukje Pharma Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See current stock price of Kukje Pharma Co Ltd for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Kukje Pharma Co Ltd's current assets represent 34.4% of total assets in 2024, an increase from 0.0% in 2011.
- Cash Position: Cash and equivalents constituted 5.2% of total assets in 2024, down from 7.8% in 2011.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2011.
- Asset Diversification: The largest asset category is accounts receivable at 13.8% of total assets.
Kukje Pharma Co Ltd Competitors by Total Assets
Key competitors of Kukje Pharma Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Kamada
TA:KMDA
|
Israel | ILA377.21 Million |
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK
|
USA | $15.42 Trillion |
|
Viatris Inc
NASDAQ:VTRS
|
USA | $35.04 Billion |
|
Takeda Pharmaceutical Company Limited
F:TKDA
|
Germany | €15.41 Trillion |
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603
|
China | CN¥14.18 Billion |
|
Chengdu Kanghong Pharmaceuticals Group Co Ltd
SHE:002773
|
China | CN¥10.21 Billion |
|
Yipinhong Pharmaceutical Co Ltd Class A
SHE:300723
|
China | CN¥4.49 Billion |
|
Avadel Pharmaceuticals PLC
NASDAQ:AVDL
|
USA | $199.45 Million |
Kukje Pharma Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.19 | 2.26 | 0.90 |
| Quick Ratio | 0.78 | 1.34 | 0.51 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | ₩11.36 Billion | ₩29.76 Billion | ₩-5.42 Billion |
Kukje Pharma Co Ltd - Advanced Valuation Insights
This section examines the relationship between Kukje Pharma Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.96 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | 1.4% |
| Total Assets | ₩165.55 Billion |
| Market Capitalization | $44.92 Million USD |
Valuation Analysis
Below Book Valuation: The market values Kukje Pharma Co Ltd's assets below their book value (0.00x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Kukje Pharma Co Ltd's assets grew by 1.4% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Kukje Pharma Co Ltd (2011–2024)
The table below shows the annual total assets of Kukje Pharma Co Ltd from 2011 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | ₩165.55 Billion ≈ $112.19 Million |
+1.40% |
| 2023-12-31 | ₩163.26 Billion ≈ $110.64 Million |
+19.52% |
| 2022-12-31 | ₩136.59 Billion ≈ $92.57 Million |
-2.28% |
| 2021-12-31 | ₩139.78 Billion ≈ $94.73 Million |
-4.01% |
| 2020-12-31 | ₩145.63 Billion ≈ $98.69 Million |
+8.20% |
| 2019-12-31 | ₩134.59 Billion ≈ $91.21 Million |
+6.62% |
| 2018-12-31 | ₩126.23 Billion ≈ $85.55 Million |
-4.11% |
| 2017-12-31 | ₩131.65 Billion ≈ $89.21 Million |
+1.69% |
| 2016-12-31 | ₩129.46 Billion ≈ $87.73 Million |
-5.26% |
| 2015-12-31 | ₩136.64 Billion ≈ $92.60 Million |
+16.28% |
| 2014-12-31 | ₩117.51 Billion ≈ $79.63 Million |
+0.07% |
| 2013-12-31 | ₩117.43 Billion ≈ $79.58 Million |
+2.18% |
| 2012-12-31 | ₩114.92 Billion ≈ $77.88 Million |
-18.85% |
| 2011-12-31 | ₩141.61 Billion ≈ $95.97 Million |
-- |
About Kukje Pharma Co Ltd
Kukje Pharma Co., Ltd. engages in manufacturing, importing, exporting, selling, and distributing pharmaceutical products. The company offers pharmaceutical products, including ETC and OTC products, raw materials, intermediates, and side chain products, as well as cosmetics and health care products. Its products include cephalosporins, quinolones, tetracycline, aminoglycosides, macrolides, other a… Read more